News & Events

Glasmacinal, a novel macrolide, was shown to be well tolerated and reduced neutrophilic inflammation in COPD patients.

The presentation, ‘EP395, a novel non-antibiotic macrolide, enhances antiviral responses in bronchial epithelial cells from asthma patients’, will highlight preclinical data produced through EpiEndo’s collaboration with Lund University.

EpiEndo Pharmaceuticals has had an article published in peer-reviewed journal, Frontiers in Allergy, highlighting the importance of the airway epithelium in lung function, both as a physical barrier and as a regulator of immune defence.

EpiEndo Pharmaceuticals has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics.

EpiEndo Pharmaceuticals is proud to participate the upcoming State Visit to Sweden, hosted by Business Iceland from 6-8 May 2025.

EpiEndo Pharmaceuticals has started a second clinical LPS challenge study with lead asset, glasmacinal (EP395).

EpiEndo Pharmaceuticals has received an INN (International Non-proprietary Name or generic name) from the World Health Organisation for its lead clinal drug candidate. EP395 has received the INN name glasmacinal.

Maria Bech, CEO of EpiEndo Pharmaceuticals will be presenting at the YAFO Capital Access China Partnering Forum on 24, 25 and 27 September 2024.